Engineered yeast pill takes on superbug c. diff in first human trial
NCT ID NCT07649096
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 5 times
Summary
This early-stage trial tests an oral capsule containing a genetically modified probiotic yeast designed to neutralize toxins produced by C. diff bacteria. The study first evaluates safety in healthy adults, then in people at risk for recurrent C. diff infection. Participants take the yeast or a placebo daily for 28 days, with close monitoring for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified probiotic yeast (FZ002)
- What this could lead to
- If it works, this could point toward a new way to prevent recurrent C. diff infections without antibiotics.
- What could go wrong
- This is a very early phase 1 safety trial, so it may not show any benefit. The yeast is genetically modified, and there are unknown risks like yeast entering the bloodstream.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIUM DIFFICILE INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New database aims to speed up FMT research for gut infections
- Should cancer patients get antibiotics for a dubious c. diff test? small trial seeks answers
- Poop pills? fecal transplants show promise for gut infections
- Poop pills? no, stool transplants aim to cure recurrent c. diff
- 4,000 patients join landmark poop transplant safety study
- Could a simple drink help clear confusion in hospitalized seniors?